Angelini Pharma appoints Sergio Marullo di Condojanni as CEO
Esme Needham | February 4, 2026 | Appointment | | Angelini Pharma, CEO
Angelini Pharma, a branch of Angelini Industries, has announced the appointment of Sergio Marullo di Condojanni as CEO.
Marullo di Condojanni has already served as CEO of Angelini Industries since 2020, and will continue to serve as CEO while also taking responsibility for the company’s pharmaceutical branch. Marullo di Condojanni brings significant leadership expertise to his new role expansion. In addition to his seven-year tenure at Angelini Industries, he holds directorial and advisory roles at a number of companies across the technology, banking and life sciences industries. These roles include Chairman of Angelini Technologies, Director of Banca Aletti and member of the advisory board of B20 Italy.
The previous CEO of Angelini Pharma, Jacopo Andreose, will now become a member of the Angelini Holding board, as well as a senior advisor to the board of Angelini Pharma.
The appointment of Marullo di Condojanni as CEO will help to drive Angelini Industries’ goal of further establishing its pharmaceutical healthcare division. Marullo di Condojanni aims to drive the company forward on key areas in this sector, including Brain Health and Consumer Healthcare. He also plans to expand the company’s global presence through strategic acquisitions for its medicines pipeline.
Thea Paolo Angelini, chair of Angelini Holding and majority shareholder, said: “Appointing Sergio as CEO will drive simplified decision-making for our pharmaceutical business – the heart of our Group. This strategic choice will enable us to be closer to market needs and, above all, to patients, by delivering greater efficiency, agility, faster decision-making and flexibility.”
Marullo di Condojanni added: “Our strategic priorities are clear: strengthen long-term competitiveness and seize transformative mergers and acquisitions opportunities that will enable us to scale globally.”
Related Content
Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies
Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global …
Angelini Pharma to acquire Arvelle Therapeutics in $960 million deal
Angelini Pharma is set to acquire Arvelle Therapeutics, a biopharmaceutical company focused on bringing innovative …
CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …
